HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soria, A. Articles by Herrera, E. Search for Related Content PubMed PubMed Citation Articles by Soria, A. Articles by Herrera, E. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 43, 74-81, January 2002
Copyright © 2002 by Lipid Research, Inc.

Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats

Correspondence to: Emilio Herrera, To whom correspondence should be addressed., eherrera{at}ceu.es (E-mail)

The level of maternal circulating triglycerides during late pregnancy has been correlated to newborns' weight in humans. To investigate the response to fenofibrate, a hypotriglyceridemic agent, in pregnant rats, 0, 100, or 200 mg of fenofibrate/kg body weight as oral doses were given twice a day from day 16 of gestation and studied at day 20. Virgin rats were studied in parallel. Liver weight was higher in pregnant than in virgin rats, and either dose of fenofibrate increased this variable in both groups. The highest dose of fenofibrate decreased fetal weight. Although plasma triglycerides decreased during the first 2 days of fenofibrate treatment in pregnant rats, the effect disappeared on day 3, and plasma triglycerides were even enhanced at day 4. In virgin rats, fenofibrate decreased plasma triglycerides throughout the experiment. Plasma cholesterol levels in pregnant rats decreased during the first 3 days of treatment, and the effect disappeared on day 4, whereas in virgin rats, values remained decreased. Changes in plasma triglycerides paralleled those of VLDL triglycerides. In pregnant rats, VLDL cholesterol levels increased while LDL cholesterol decreased with the treatment, whereas in virgin rats, cholesterol levels decreased in all lipoprotein fractions. Only in virgin rats did liver triglyceride concentration increase with fenofibrate treatment. Lumbar adipose tissue LPL was lower in pregnant than in virgin rats, and fenofibrate treatment decreased this variable in both groups. Maternal fenofibrate treatment increased fetal plasma and liver triglyceride and cholesterol concentrations.

It is proposed that the opposite effects of fenofibrate treatment in virgin and pregnant rats are a consequence of both the enhanced liver capability for VLDL triglyceride production and a rebound response to the drug in the latter. — Soria, A., C. Bocos, and E. Herrera. Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats. J. Lipid Res. 2002. 43: 74–81.

Supplementary key words: pregnancy, fibrates, triglyceride, VLDL triglyceride, cholesterol, lipoprotein lipase, rat

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N Martinez, E Capobianco, V White, M C Pustovrh, R Higa, and A Jawerbaum Peroxisome proliferator-activated receptor {alpha} activation regulates lipid metabolism in the feto-placental unit from diabetic rats Reproduction, July 1, 2008; 136(1): 95 - 103. [Abstract] [Full Text] [PDF]

				C. R. Waites, M. A. Dominick, T. P. Sanderson, and B. E. Schilling Nonclinical Safety Evaluation of Muraglitazar, a Novel PPAR{alpha}/{gamma} Agonist Toxicol. Sci., November 1, 2007; 100(1): 248 - 258. [Abstract] [Full Text] [PDF]

				M. J. Holness, N. D. Smith, G. K. Greenwood, and M. C. Sugden PPAR{alpha} activation reverses adverse effects induced by high-saturated-fat feeding on pancreatic beta-cell function in late pregnancy Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1087 - E1094. [Abstract] [Full Text] [PDF]

				M. J. Holness, G. K. Greenwood, N. D. Smith, and M. C. Sugden Peroxisome Proliferator-Activated Receptor-{alpha} and Glucocorticoids Interactively Regulate Insulin Secretion During Pregnancy Diabetes, December 1, 2006; 55(12): 3501 - 3508. [Abstract] [Full Text] [PDF]

				M. C. Sugden and M. J. Holness Potential Role of Peroxisome Proliferator-Activated Receptor-{alpha} in the Modulation of Glucose-Stimulated Insulin Secretion Diabetes, February 1, 2004; 53(90001): S71 - 81. [Abstract] [Full Text]

				M. C. Sugden, G. K. Greenwood, N. D. Smith, and M. J. Holness Peroxisome Proliferator-Activated Receptor-{alpha} Activation during Pregnancy Attenuates Glucose-Stimulated Insulin Hypersecretion in Vivo by Increasing Insulin Sensitivity, without Impairing Pregnancy-Induced Increases in {beta}-Cell Glucose Sensing and Responsiveness Endocrinology, January 1, 2003; 144(1): 146 - 153. [Abstract] [Full Text] [PDF]